Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
NCT00712582 is a phase 2 interventional trial sponsored by Memorial Sloan Kettering Cancer Center. As of 21 Nov 2026, it is completed. It studies Etoposide and Rituximab in Non-Hodgkin's Lymphoma. The registry lists an enrollment of 96 participants at 1 site in 1 country. The registry lists a start date of 1 Jul 2008 and a primary completion date of 12 Mar 2021. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00712582 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
| Enrollment | 96 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Non-Hodgkin's Lymphoma |
| Drugs | Etoposide and Rituximab |
| Start | 1 Jul 2008 |
| Primary completion | 12 Mar 2021 |
| Study completion | 12 Mar 2021 |
| Last update posted | 21 Jun 2022 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Memorial Sloan Kettering Cancer Center
New York
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00712582
Each answer restates registry values shown on this page.
What is NCT00712582?
NCT00712582 is a phase 2 interventional trial sponsored by Memorial Sloan Kettering Cancer Center. It studies Etoposide and Rituximab in Non-Hodgkin's Lymphoma.
Who leads NCT00712582?
The registry names Andrew Zelenetz, MD, PhD (principal investigator, Memorial Sloan Kettering Cancer Center) as the overall official.
Where does NCT00712582 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00712582 study?
The registered drug and biological interventions are Etoposide and Rituximab.
When did NCT00712582 end?
The registry lists a primary completion date of 12 Mar 2021 and a study completion date of 12 Mar 2021. The sponsor last updated the record on 21 Jun 2022.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.